Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

Study Identifier
MAP0020-CL-P201
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Asthma
  • Study Drug
  • 84ug MAP0020
  • 42ug MAP0020
  • 21ug MAP0020
  • Phase
    Phase 2
    Sex
    Female & Male
    Age
    4 - 11 Years

    Protocol Summary

    This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation aerosol delivery.

    Study Locations

    Location
    Status
    Location
    West Coast Clinical Trials LLC
    Cypress, California, United States
    Status
    Not applicable
    Location
    Sylvana Research Associates
    San Antonio, Texas, United States
    Status
    Not applicable